Strata Critical Medical price target raised to $7.25 from $6.50 at Lake Street

Lake Street raised the firm’s price target on Strata Critical Medical (SRTA) to $7.25 from $6.50 and keeps a Buy rating on the shares. The firm is “highly supportive” of the announced acquisition of Keystone Perfusion Services for $124M pre-earnout, as it successfully addresses a concern of how post-Passenger Strata could truly deploy its massive $235M pro forma cash position in a material way via M&A, the analyst tells investors in a research note.